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Abstract 
Purpose: Malnutrition is a very common problem in oncology patients, and is associated with many negative 
consequences including poorer prognosis, quality of life and survival. However, malnutrition in oncology 
patients is often overlooked although there is growing evidence showing that it can be prevented or reduced 
through nutrition intervention. This paper aims to provide an updated review on the effectiveness of different 
nutrition intervention approaches on nutrition status outcomes in oncology patients. 
Methods: Randomised controlled trials (RCTs) published between 1994 and 2014 which examined the effects 
of nutrition intervention approaches – in particular, nutrition counselling (NC), oral nutrition supplements 
(ONS) and tube feeding (TF) – on nutrition status outcomes of oncology patients were identified and reviewed. 
Results: Thirteen papers from 11 RCTs with a total of 1077 participants were included. The intervention 
approaches included NC (4 studies), NC+ONS (5 studies), ONS (3 studies) and TF (3 studies). The various 
results suggest that NC with or without ONS was associated with consistent improvements in several nutrition 
status outcomes. On the other hand, ONS and TF were associated with inconsistent improvements in few 
aspects of nutrition status outcomes. 
Conclusions: The referral of oncology patients for NC is recommended given the strong evidence of its 
beneficial effects on the prevention and reduction of malnutrition. Other forms of nutrition support including 
ONS and TF may then be included if deemed suitable and necessary for the individual. 
 
Keywords: Nutrition intervention; Nutrition status; Nutrition counselling; Oral nutrition supplements; Tube 
feeding; Cancer 
 
Abbreviations: ADA-MNT, American Dietetic Association Medical Nutrition Therapy; BMI, body mass index; 
CRT, chemoradiotherapy; CT, chemotherapy; EPA, eicopantaenoic acid; FFM, fat-free mass; GR, group 
rehabilitation; IS, individual support; ISGR, individual support; and group rehabilitation; NC, nutrition 
counselling; NGT, nasogastric tube feeding; NI, no intervention; ONS, oral nutrition supplements; PEG, 
percutaneous endoscopic gastrostomy feeding; PG-SGA, patient-generated subjective global assessment; PPDI, 
patient-participation-based dietary intervention; QoL, quality of life; RCT, randomised controlled trial; RT, 
radiotherapy; TF, tube feeding; UC, usual care 
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1.0 Introduction 
Malnutrition is prevalent in oncology patients with incidence ranging from 40% to 80% [1-3]. Malnutrition in 
cancer patients may be caused by multiple factors, including response to the tumour and cancer treatments [4-6] 
as well as emotional and psychological changes in the patient [7]. Food aversion may also result from altered 
taste perception following cancer treatments such as chemotherapy and radiotherapy [8,9]. Furthermore, 
individuals with cancers affecting the head, neck and gastrointestinal system may experience pain and 
discomfort during food consumption, resulting in reduced food intake [10] as well as poorer nutrient uptake and 
utilisation caused by decline in digestive organ function. Consequently, patients with these types of cancers are 
at the greatest risk of malnutrition [11].  
Malnutrition leads to adverse consequences such as poorer prognosis and treatment outcome [11,12], 
reduced functional status [13,14], reduced quality of life (QoL)1 [10,14], increased risk of chemotherapy-
induced toxicity [11] and post-operative complications [16]. These malnutrition-associated consequences of 
cancer in turn lead to poorer survival [17]. Furthermore, malnutrition was also associated with longer duration 
of hospital stays, poorer hospitalisation outcomes and higher healthcare costs [2].  
Malnutrition in oncology patients often involves cancer cachexia, which is characterised by progressive 
muscle wasting that cannot be completely reversed by conventional nutrition support [18]. This condition is 
often accompanied by anorexia, reduced food intake, metabolic abnormalities, fatigue as well as impaired 
immune and physical function [18,19] which exacerbates the condition of the patient.  
Despite its high incidence and adverse effects, malnutrition in oncology patients is an often overlooked 
condition that should be addressed with early and systematic nutrition support [3,14,17]. Early and sustained 
nutrition intervention has been shown to be effective in reducing weight loss [20,21,15] and alleviating 
malnutrition-associated effects including improving tolerance to cancer treatment, reducing incidence of 
hospital admission [20] and improving QoL [15,22]. At present, the main nutrition intervention approaches used 
for oncology patients includes nutrition counselling (NC) by a dietitian or other healthcare professionals [21], 
prescription of oral nutrition supplements (ONS) [5,23] as well as tube feeding (TF). These interventional 
approaches may be used alone or in combination. This review will critically evaluate the effectiveness of the 
different methods of nutrition intervention on nutrition status outcomes based on existing literature.  
                                                 
1 Quality of life (QoL) of patients are assessed using questionnaires with different items such as physical, 
emotional and social function as well as patient symptoms [15]. 
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2.0 Materials and Methods 
2.1 Database search 
Original research articles published from 1994 to 2014 which studied the effects of nutrition intervention 
approaches (i.e. NC, ONS and TF) on outcomes of oncology patients were sourced from electronic databases 
including PubMed (MEDLINE), the Cochrane Central Register of Controlled Trials (CENTRAL), the American 
Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) and the Academy of Nutrition and Dietetics (AND) 
Evidence Analysis Library. The primary outcomes analysed in this review are nutrition status outcomes (e.g. 
weight, patient-generated subjective global assessment (PG-SGA)2, body mass index (BMI) and muscle mass) 
though other outcomes (e.g. mortality, infection and QoL) were also explored. The exposure search terms used 
were ‘nutrition intervention’, ‘oral nutrition supplementation’, ‘nutrition therapy’, ‘enteral nutrition’, ‘tube 
feeding’ ‘gastrostomy feeding’, ‘jejunostomy feeding’, ‘nutrition counselling’, ‘dietary counselling’, ‘dietitian 
counselling’ and the outcome search terms used were ‘malnutrition’, ‘nutrition status’, ‘weight’, ‘BMI’ and 
‘SGA’. Studies on parenteral nutrition were excluded as practice guidelines recommend parenteral nutrition to 
be used only when the gastrointestinal tract is unable to function [24]. 
2.2 Selection of studies 
The inclusion and exclusion criteria are listed in Table 1. Only randomised controlled trials (RCTs) and pseudo-
randomised trials (trials which used quasi-random allocation methods such as assignment by postal code) were 
included. The studies had to involve adult oncology patients (>19 years). Patients of all types and stages of 
cancer, as well as receiving all types of oncology treatments (e.g. radiotherapy (RT), chemotherapy (CT), 
surgery) were included. The selection criteria for papers included in the systematic review are summarised in 
Figure 1. We did not perform a meta-analysis due to the high degree of heterogeneity between the studies. 
 
Table 1: Inclusion and exclusion criteria of papers included in review 
Selection criteria Inclusion criteria Exclusion criteria 
Type of studies RCTs and pseudo-randomised trials Non-randomised trials; non-controlled 
trials; animal trials; in-vitro studies etc. 
Patient 
characteristics 
Adults (> 19 years) 
All types and stages of cancer 
Receiving all types of oncology treatments 
(e.g. RT, CT, surgery) 
All types of settings (e.g. out-patient and 
hospitals) 
Infants and children (≤ 19 years) 
 
Type of nutrition 
intervention 
NC and/or ONS (to increase energy and 
protein intake but not to modulate the 
immune function) and TF 
ONS (to modulate the immune function); 
parenteral nutrition; drug interventions 
etc. 
Outcomes studied Nutrition status (e.g. weight, BMI, PG-
SGA score) and others, if any 
 
Abbreviations: BMI, body mass index; CT, chemotherapy; NC, nutrition counselling; ONS, oral nutrition 
supplements; PG-SGA, patient-generated subjective global assessment; RCTs, randomised controlled trials; RT, 
radiotherapy; TF, tube feeding 
                                                 
2 Patient-generated subjective global assessment (PG-SGA) is a nutrition status assessment tool based on the 
dietary intake, weight change, functional capacity, symptoms and physical examination that has been validated 
for use on cancer patients. After the assessment, patients are classified as well-nourished (A), moderately 
malnourished (B) and severely malnourished (C) [20]. A numerical PG-SGA score is also given, with higher 
scores indicating poorer nutrition status [12]. 
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Figure 1: Flow diagram for selection of studies 
  
Abstracts identified 
through Pubmed search 
(n= 248) 
Total abstracts after removing duplicates 
(n = 632) 
Abstracts excluded 
(n = 490) 
Trials included in this review 
(n = 13) 
Abstracts identified 
through CENTRAL search 
(n = 482)
Abstracts identified 
through references 
(n = 20) 
Full-text articles screened for inclusion 
(n = 142)
Full-text articles excluded 
(n = 129) 
Abstracts screened for inclusion 
(n = 632)
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3.0 Results 
3.1 Literature search 
Thirteen papers with a total of 1077 participants were included. Four papers originated from two trials [25-28], 
with a short-term [26] and long-term study [25] of colorectal cancer patients as well as a single study on 
gastrointestinal tract as well as head and neck cancer patients which reported on different nutrition status 
outcomes in two papers [27,28]. As such, there were 11 RCTs that were included in the review. The intervention 
approaches included NC (4 studies; 5 papers) [25,26,29-31], NC+ONS (5 studies; 6 papers) [21,23,27-29,32], 
ONS (3 studies; 4 papers) [25,26,29,31] and TF (3 studies; 3 papers) [15,33,34]. All the papers reviewed are 
summarized in Table 2. 
3.2 Nutrition counselling  
The first approach commonly used to prevent or manage malnutrition is nutrition counselling (NC), which is the 
provision of individualised advice to patients to modify or enhance their diet. Dietitians and other healthcare 
professionals may provide patients and their caregivers’ advice on ways to increase the patient’s calorie and 
protein intake through regular foods as well as encourage certain modifications to the patient’s current diet. 
Furthermore, NC allows for nutrition advice based on each patient’s health condition and lifestyle [29]. Here, 
we first review the effectiveness of NC with no prescription of ONS by the dietitian. 
All the four studies that investigated the effect of NC (with no ONS prescription) on nutrition status 
[25,26,29-31] reported positive effects of NC on different aspects of nutrition status including weight gain [29], 
PG-SGA scores [25,26,30,31] and BMI [25]. However, no significant difference in weight, BMI as well as 
triceps and scapular muscle mass change over 12 weeks was found between the NC and control groups although 
improvements in PG-SGA was reported following intervention in one study [30]. In another study which also 
reported improvements in PG-SGA, no significant difference in the number of patients who showed 
improvements in BMI between the NC and control groups was found [26].  
Significant improvement in energy and protein intake was noted among NC patients as compared to control 
patients in all four papers that included nutrition intake as an outcome [25,26,30,31]. Nutrition intake was also 
correlated with nutrition status [31]. Four of the five papers that included QoL as an outcome found 
improvements in QoL function scores [25,26,30,31], with only one paper reporting no significant difference 
between groups for QoL change from baseline to week 6 and week 26 [29]. Furthermore, QoL change was also 
correlated with nutrition intake or status change in three papers [25,26,31]. NC was consistently associated with 
patients experiencing fewer [25,26,31] and less severe RT toxicity symptoms [25,31]. In one paper, survival in 
colorectal cancer patients who received NC improved [25] while in another paper, no significant difference 
between both groups of patients were found [29].  
3.2 Nutrition counselling with oral nutrition supplements 
While there is evidence that NC alone improves nutrition status outcomes and other clinical outcomes of 
patients, the combined use of NC with ONS is usually recommended for oncology patients. This is especially 
for patients who have difficulties meeting the recommended nutrition intake through consumption of regular 
foods. In this section, we review the effectiveness of NC with ONS as recommended by the dietitian on the 
nutrition status of oncology patients. 
Five studies (6 papers) investigated the effect of NC+ONS on nutrition status outcomes [21,23,27-29,32]. In 
one paper [29], although there was a group of patients who received NC+ONS, there was no specific 
comparison of this group of patients against those who received no form of intervention. It was only reported 
that the patients who received NC showed greater weight gain compared to those who did not [29]. The other 
five papers showed that the intervention approach (NC+ONS) was associated with improvements in nutrition 
status outcomes including weight gain [32], weight maintenance [21,23,28], BMI gain [32], PG-SGA 
improvement [27,28] and fat free mass (FFM) maintenance [23]. However, in three of the papers [21,23,28], no 
significant differences in BMI [21], FFM loss [28] and fat mass loss [23] was observed between the control and 
intervention groups. 
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The only paper which reported on nutrition intake as an outcome found that NC+ONS was associated with 
an increase in energy and protein intake [27]. As for QoL, one paper found that the intervention approach was 
associated with improvements in the maintenance of global QoL and physical function [28] while two other 
papers found no significant improvements in QoL [29,32]. Survival was not significantly different between 
patients who received NC+ONS compared to those who did not in both papers which reported on survival as an 
outcome [29,32]. 
3.3 Oral nutrition supplements  
Oral nutrition supplementation without NC may also be used to increase caloric and protein intake of patients 
[26,29,31,35]. ONS is usually used to supplement the regular diet, although they may act as a meal replacement 
for patients who are unable to consume regular foods.  
Three studies (4 papers) investigated the effect of ONS on the nutrition status of oncology patients in terms 
of weight, BMI and PG-SGA scores [25,26,29,31]. In all four papers, ONS was associated with improvements 
in nutrition status outcomes compared to the control group though these improvements were mostly not 
statistically significant [25,26,29,31].  
Only one paper found statistically significant improvements in BMI and PG-SGA scores in patients who 
received ONS compared to control patients [26] while two other studies found no significant improvements in 
weight gain [29] and PG-SGA scores [31]. Another long-term follow up study did not report clearly whether 
ONS was associated with any improvements in nutrition status [25]. 
Only one of three papers reporting on nutrition intake found significant improvements in patients using ONS 
[26]. However, the long-term follow-up [25] of that study and another short term study [31] found no significant 
difference in nutrition intake in both groups. The paper that reported positive results also found that the intake 
eventually decreased to baseline or below baseline for both the ONS and control groups after 3 months [26]. 
Caloric and protein intake were positively correlated with nutrition status in both groups in one of the papers 
[31]. Two studies found short-term improvements in some QoL scores in the ONS group when compared to the 
control group which showed deterioration in all QoL scores [26,31]. Two other studies [25,29] found no 
significant difference in QoL between both groups. In three [25,26,31] of four papers, QoL change was 
associated with nutrition intake or status change in ONS patients [26,31]. One study found that ONS reduced the 
incidence of anorexia, nausea, vomiting and diarrhoea after RT and 3 months [26]. However, the long-term 
follow-up [25] of the same study and another short-term study [31] found no significant difference between the 
ONS and control groups. One paper reported better survival in ONS patients [25] while another found no 
significant difference between the ONS and control groups [29]. 
3.4 Tube feeding 
Tube feeding (TF) is another nutrition intervention that is mostly used for oncology patients who have problems 
with oral consumption. This includes many head and neck cancer patients as the tumour may physically obstruct 
the passage of food or cause difficulties and pain during swallowing, resulting in reduced nutrition intake [15]. 
Liquid nutrition formulations are delivered to the patient’s stomach or small intestine by means of a tube that is 
either placed through the nostril, with the most common being nasogastric tube feeding (NGT), or a tube that 
goes through the abdomen wall directly, with the most common being percutaneous endoscopic gastrostomy 
(PEG). However, there is also concern about the complications that are associated with tube feeding which 
include infections and tube dislodgement [33].  
Three studies examined the effects of TF on nutrition status outcomes in oncology patients, in particular 
head and neck cancer patients [15,33,34]. Two studies compared patients who were randomised to either PEG or 
usual care [15,34] while another study compared patients who were randomised to either PEG or NGT [33]. No 
RCTs on the comparison of NGT patients with control patients or on other forms of TF such as nasojejunal 
feeding and jejunostomy were found. 
Mixed results were found in the two papers that compared patients who received PEG feeding to those who 
received usual care [15,34]. Only one paper found positive results associated with PEG feeding in terms of 
weight maintenance [15] while both papers found no significant difference in BMI between PEG patients and 
control patients [15,34]. In the paper comparing NGT and PEG on nutrition status outcomes [33], patients who 
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received PEG feeding showed better weight maintenance and larger triceps skinfold thickness at 6 weeks post-
treatment though there was no improvement in absolute weight or upper arm circumference at the same time 
point. The difference in weight maintenance also ceased to be significant at 6 months post-treatment [33].  
The two papers comparing PEG with usual care reported on QoL as an outcome and found improvements in 
QoL in general at 6 months [34] and several QoL functions at 3, 6 and 12 months [15]. No significant 
differences in overall complication rates and chest infection rates were found between the PEG and NGT groups 
[33] though tube dislodgement occurred in 12 NGT patients and none of the PEG patients. Mortality was not 
found to be significantly different between the PEG and NGT patients [33]. 
4.0 Discussion 
4.1 Summary of key findings 
It has been demonstrated that different nutrition intervention approaches have differing degrees of effectiveness 
on nutrition status outcomes as well as other clinical outcomes. In particular, NC with or without ONS has been 
associated with consistent improvements in different aspects of nutrition status outcomes including weight gain 
and maintenance, BMI and PG-SGA change. On the other hand, ONS on its own was associated with slight but 
mostly insignificant improvements in aspects of nutrition status outcomes like weight gain, BMI and PG-SGA 
scores, with only one paper finding significant improvements in BMI and PG-SGA scores. PEG was associated 
with inconsistent improvements in nutrition status outcomes with one paper finding improvements in weight 
maintenance and both papers finding no improvements in BMI. In the single study that compared PEG with 
NGT, PEG patients showed better weight maintenance and greater triceps skinfold thickness at 6 weeks than 
NGT patients though the difference in weight maintenance ceased to be significant at 6 months. Furthermore, 
there were no significant differences in other nutrition status outcomes such as absolute weight and upper arm 
circumference between the PEG and NGT patients.  
4.2 Analysis of results 
Nutrition counselling (NC) with or without ONS was associated with much more consistent and significant 
improvements in nutrition status outcomes compared to other forms of nutrition intervention (e.g. TF or ONS 
alone) or no intervention. In advanced stage cancer patients, nutrition intervention is usually only able to reduce, 
rather than reverse, weight loss [36,37]. Although all the studies on NC involved patients with advanced stage 
cancers [21,23,25-32], improvements in weight maintenance [23,28], and even weight gain [29,32], were 
observed, thus highlighting the efficacy of NC in improving nutrition status outcomes. 
This could be because NC patients adhere more strictly to the recommended dietary changes due to regular 
appointments with dietitians or other healthcare professionals [38]. Other than providing dietary advice, these 
healthcare professionals are likely to also provide encouragement and positive reinforcement to patients which 
are important in supporting the dietary change of the patient [39]. On the other hand, other forms of intervention 
such as ONS lack constant review and support, possibly contributing to the problem of non-compliance. 
Furthermore, unlike most other nutrition interventional approaches, dietary advice given during NC is 
individualised to suit the lifestyle and condition of patients and may alter based on changes in the patient’s 
conditions [38]. 
ONS was only associated with significant improvements to nutrition status outcomes such as BMI and PG-
SGA scores in a study on colorectal cancer patients [26]. However, another study on head and neck cancer 
patients conducted by the same group of researchers which was executed in a comparable manner (same 
prescription of ONS, duration of intervention, similar mean age of patients and proportion of stage I/II patients 
and stage III/IV patients) showed no significant improvements in weight gain [31]. This could suggest that at 
least in the short term, colorectal cancer patients are receptive to this form of nutrition intervention approach, 
unlike head and neck cancer patients. However, there is also the possibility that head and neck cancer patients 
did not show positive changes in nutrition status outcomes upon ONS prescription as they were less compliant 
to the ONS prescription due to pain or discomfort during consumption of regular food and ONS [10].  
Another study on patients with advanced gastrointestinal tract cancer, non-small cell lung cancers or 
mesothelioma also found no significant improvements in weight change at 6 weeks, 26 weeks and 1 year upon 
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the prescription of ONS [29]. Overall, there is little evidence to show that ONS alone is effective in improving 
nutrition status outcomes in oncology patients. Furthermore, while ONS has the advantage of being one of the 
simplest methods to increase caloric intake [38], it may be financially unsustainable in the long term for some 
patients and often has the problem of non-compliance [35]. 
There was also insufficient evidence to show that TF was effective in improving nutrition status outcomes in 
oncology patients. In both studies comparing PEG to usual care, no significant improvements in several 
nutrition status outcomes including BMI and number of malnourished patients were observed [15,34]. The only 
positive outcome associated with PEG was significantly less weight loss at 6 months among patients who lost 
weight [15]. However, it is important to note that only advanced cancer patients were included in these two 
studies [15,34]. Early stage cancer patients have been found to be more receptive to nutrition intervention 
approaches than advanced stage cancer patients [36]. As such, while TF may be ineffective in improving 
nutrition status outcomes for advanced stage cancer patients [15,34], it is possible that TF may be effective for 
early stage cancer patients.  
The only study that compared NGT feeding against PEG feeding [33] found that PEG patients showed better 
nutrition status outcomes including weight maintenance and triceps skinfold thickness than NGT patients 
though there were no significant differences in other nutrition status outcomes [33]. However, the small number 
of RCTs and sample size of the studies available contribute to the inconclusiveness of the actual efficacy of TF 
on nutrition status outcomes [15,33,34]. 
 
4.3 Comparison of main findings with other reviews 
A comprehensive literature search yielded no reviews that focused on the effects of nutrition intervention 
approaches on nutrition status outcomes of oncology patients in general (i.e. not focused specifically on a type 
of cancer) which only used RCTs. However, there were two reviews which focused on head and neck cancer 
patients conducted by Langius et al. [40] (10 RCTs; n= 536) and Garg et al. [41] (10 RCTs; n= 585). Both 
reviews examined the efficacy of nutrition intervention approaches on nutrition status outcomes in head and 
neck cancer patients receiving RT [41] and RT or CRT [40]. Similar to the present review, NC was associated 
with consistent improvements in nutrition status while ONS was associated with inconsistent effects on nutrition 
status outcomes [40]. The present review is also in agreement with the review by Langius et al. which found that 
PEG was not associated with consistent benefit to nutrition status when compared to control (received TF 
[15,34] and NC [15] only when required) and was associated with some nutrition status improvements after RT 
when compared to NGT [40]. Evidence on the efficacy of TF on nutrition status outcomes was also very limited 
in the review by Garg et al. [46], with only one study comparing patients who received NGT against those who 
received optimal oral nutrition [42]. In that study, NGT patients showed significantly less weight loss. However, 
due to limited number of studies and sample size, no definite conclusion on the efficacy of TF on nutrition status 
could be drawn as well. 
 
4.4 Limitations 
The different studies that were included in the present review had a high degree of heterogeneity including 
variations in cancer type and staging, intervention duration, frequency and intensity as well as inclusion criteria 
for participants. In particular, the variability in cancer types and stages of the patients from the different studies 
is likely to account for a large part of the differences in results. The risk and severity of malnutrition differs with 
cancer type [11], with lung and upper gastrointestinal tract cancer patients showing a higher incidence of 
cachexia than lower gastrointestinal tract cancer patients [43]. In addition, patients with advanced stage cancers 
tend to show less improvement in nutrition status compared to patients with early stage cancers [36]. As such, 
patients of different types and stages of cancers are likely to show different extents of nutrition status 
improvement in response to the same nutrition intervention. 
Furthermore, the definition of the control groups differed greatly, with some studies using no intervention 
[25,26,29,31] and others using usual care [21,15,23,27,28,30,32,34] as the control.  This is because in most 
situations, it is unethical to completely deny patients of any form of nutrition intervention, especially when the 
patient is malnourished or at risk of malnutrition. In different studies, the protocol for usual care also varied 
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greatly for different countries and hospitals. This high degree of heterogeneity among the studies may contribute 
to the differences in outcomes in different studies of the same intervention approach. 
In particular, there is a high degree of heterogeneity in the execution of NC given its very nature of being 
individualised and dependent on individual judgement. The type of advice provided as well as the way the 
advice was delivered to the patient differs greatly depending on the experience, discernment [44] and even soft 
skills of the dietitian. These in turn are strongly influenced by the conventions of the region, hospital protocols, 
training received by the dietitian and the dietitian himself/ herself. Furthermore, while the duration and 
frequency of NC is commonly reported in studies, it is difficult and almost impossible to document other aspects 
including the content and intensity of NC. Despite all these differences, the fact that consistent nutrition status 
improvements were observed in all NC studies is proof of its efficacy in reducing malnutrition. 
The review also did not encompass certain aspects of nutrition intervention such as parenteral nutrition and 
some novel nutrition intervention methods. Parenteral nutrition was excluded as practice guidelines recommend 
parenteral nutrition to be used only when the gastrointestinal tract is unable to function [24]. Other novel 
nutrition intervention methods which involve the use of immune function modulating ONS such as 
eicosapentaenoic acid (EPA) as well as pharmacological drugs like megestrol acetate were also excluded from 
the study as these compounds affect the nutrition status and other outcomes of patients through mechanisms 
other than the increase in caloric or protein intake. In particular, there is some evidence that EPA can alter the 
metabolic pathways involved in cancer [45] while megestrol acetate helps to stimulate appetite and may also 
alter metabolism and catabolic cytokine production [46]. 
4.5 Future directions 
The RCTs of nutrition intervention approaches, especially for TF, on nutrition status outcomes are still very 
limited. As such, more studies are required to provide more definitive evidence with regard to the efficacy of 
these approaches. The multiple factors present in the studies which may influence outcomes also make it 
difficult for comparison between different studies. Future research may take these factors into consideration by 
adjusting a single factor (e.g. duration or intensity of intervention) and studying whether it affects outcomes. 
5.0 Conclusion 
From this review, NC with or without ONS appeared to be the most effective nutrition intervention method, 
with significant and consistent improvements in several nutrition status outcomes. On the other hand, ONS and 
TF were associated with inconsistent results, with improvements in few aspects of nutrition status outcomes and 
no significant differences in others. More studies are, however, required to provide a more concrete conclusion. 
At present, it is recommended that a systematic protocol be in place for the early referral of oncology patients to 
dietitians for NC in order to reduce their risk and severity of malnutrition which could be detrimental to other 
clinical outcomes such as survival and QoL. Individualised advice on whether other nutrition intervention 
approaches such as ONS and TF are required can then be provided based on the condition of the patient. 
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Table 2: Summary of RCTs studying the effect of nutrition intervention approaches on nutrition status outcomes of oncology patients 
Author, 
date 
n Main inclusion 
criteria 
Intervention Length of 
follow-up 
Nutrition status outcomes Other outcomes 
Baldwin 
et al., 
2011 [29] 
358 Advanced 
gastrointestinal tract 
cancer, non-small cell 
lung cancer or 
mesothelioma; CT; 
Weight loss in the last 
3 months 
(A) NI 
(B) NC (to increase food 
intake by 600kcal/day) 
(C) ONS (powder mix 
providing 588 kcal/day in 
240mL of full-cream milk + 
multivitamin and mineral 
supplement) 
(D) NC and ONS 
 
Start: Before start of CT 
Duration: 6 weeks 
52 weeks Weight gain at 1 year: Greater in patients who 
received NC than those who did not on an as 
treated basis (4.78 kg vs. 7.5 kg, P = .04); 
Greater in patients who received ONS 
compared to those who did not though this 
difference was not statistically significant.  
One-year survival, QoL change from 
baseline to 6 and 26 weeks and hand grip 
strength: No significant difference between 
groups. 
Kim et 
al., 2014 
[30] 
56 Stomach cancer 
(Stage I to III); 
Gastrectomy 
(A) PPDI (includes NC by 
nurses) 
(B) UC 
 
Start: One day before hospital 
discharge 
Duration: 6 weeks 
3 months Change in PG-SGA: Greater decrease 
(improvement) in PPDI group than UC group (-
5.73 vs. -3.91, P = 0.003); Weight and BMI 
deterioration over 12 weeks: No significant 
difference; Triceps muscle mass: No 
significant difference. 
Nutrition intake: Improved in PPDI group; 
Functional and performance status: 
Improved in PPDI group; Adverse dietary 
symptoms: Fewer in PPDI group than UC 
group (P < .05). 
Ravasco 
et al., 
2012 [25] 
89 Colorectal cancer; 
Neoadjuvant RT 
(A) NC 
(B) ONS (400 mL/day of high 
protein and energy dense 
liquid formulation providing 
400kcal and 40 g protein) 
(C) NI 
 
Start: After starting RT 
Duration: 6 weeks 
(throughout RT) 
6.5 years Deterioration in PG-SGA and BMI at ~6.5 
years follow-up: More prevalent in ONS and 
NI groups than NC group (P < .002); 
Maintenance or improvement in PG-SGA 
and BMI at ~6.5 years follow-up: More 
prevalent in NC group than ONS and NI groups 
(P < .005). 
Energy and protein intake at 3 months 
after RT Greater in NC group than ONS and 
NI groups which were similar to each other (P 
< .002); Change in energy and protein 
intake after ~6.5 years: Maintained in NC 
group but decreased for ONS and NI groups 
(P < .06); QoL: Better in NC group than ONS 
and NI groups which were similar to each 
other (P < .002); Better QoL was associated 
with maintenance of adequate intake and 
nutrition status (P < .002); 
Disease-specific median survival: Longer in 
11 
 
Author, 
date 
n Main inclusion 
criteria 
Intervention Length of 
follow-up 
Nutrition status outcomes Other outcomes 
NC group than ONS group which was in turn 
longer than NI group (7.3 y vs. 6.5 y vs. 4.9 y, 
P < .05); 
Late RT toxicity: Less prevalent and severe 
in NC group than ONS and NI groups which 
were similar to each other (P < .002). 
Ravasco 
et al., 
2005 [31] 
75 Head and neck 
cancer; RT 
(A) NC 
(B) ONS (400 mL/day of high 
protein and energy dense 
liquid formulation providing 
400kcal and 40 g protein) 
(C) NI 
 
Start: After starting RT 
Duration: 6 weeks 
(throughout RT) 
3 months Number of patients who showed further PG-
SGA deterioration at end of RT and 3 
months: Fewer in NC group than ONS and NI 
groups (P < .002); Number of patients who 
maintained or showed improvements in PG-
SGA scores both at the end of RT and 3 
months: Greater in NC group than ONS and NI 
groups (P < .001); Proportion of 
malnourished patients at baseline who 
improved in nutrition status: 50% in NC 
group at 3 months, with an average recovery of 
4 kg; None in ONS and NI group. 
Energy and protein intake: Increased in NC 
and ONS groups from baseline to end of RT 
(P ≤ .05), with a larger increase in energy 
intake in NC group (P = .005); Decreased in 
NI group (P < .01); Intake at 3 months was 
maintained in NC group (P < .05) but 
decreased to baseline or below baseline in 
ONS and NI groups (P = .005); Intake 
correlated with nutrition status (P ≤ .002); 
Proportion of patients who experienced 
fewer or less severe RT-induced morbidity: 
Greater in NC group than ONS or NI groups 
(90% vs. 67% vs. 51%, P < .0001); QoL 
after RT: Improved in NC and ONS groups 
(P < . 003) but deteriorated in NI group (P < 
.05); Changes in QoL scores proportional to 
nutrition intake and status in all groups (P < 
.05); Change in overall QoL in 3 months 
after RT: Maintained or improved in NC 
patients but maintained or worsened in ONS 
and NI patients. 
Ravasco 
et al., 
2005 [26] 
111 Colorectal cancer; 
Neoadjuvant RT 
(A)NC 
(B) ONS (400 mL/day of high 
protein and energy dense 
liquid formulation providing 
400kcal and 40 g protein) 
(C) NI 
3 months Number of patients who deteriorated in PG-
SGA scores at the end of RT and 3 months: 
Smaller in NC group than ONS and NI groups 
(P < .002); Number of patients who 
maintained or improved in PG-SGA scores 
at the end of RT and 3 months: Greater in NC 
Energy and protein intake at end RT: 
Increased for NC and ONS groups (P ≤ .04) 
with a greater increase in energy intake in NC 
than ONS group (555 kcal/d vs. 296 kcal/d, P 
= .001) but decreased for NI group (P < .01); 
Energy and protein intake at 3 months: 
12 
 
Author, 
date 
n Main inclusion 
criteria 
Intervention Length of 
follow-up 
Nutrition status outcomes Other outcomes 
 
Start: After start of RT 
Duration: 6 weeks 
(throughout RT) 
group than ONS and NI groups (P < .001); A 
similar trend was observed for BMI though the 
difference was not statistically significant; 
Number of malnourished patients (at 
baseline) who deteriorated in both PG-SGA 
and BMI at the end of RT and 3 months: 
Lower in NC group than ONS group (P < .001) 
which was in turn lower than NI group (P < 
.008); Number of malnourished patients (at 
baseline) who improved in PG-SGA scores at 
3 months: 9 out of 15 malnourished patients in 
NC group; None in ONS and NI groups. 
Maintained in NC group but decreased to 
baseline or below baseline  in ONS and NI 
groups (P ≤ .06); Incidence of RT toxicity at 
end RT and 3 months: Greater in UC group 
than NC and ONS groups (P < .05); Change 
in QoL at end RT and 3 months: 
Improvements in all function scores in NC 
group, some function scores in ONS group 
and deterioration in all function scores in NI 
group; Improvement or deterioration in QoL 
scores were correlated with improved or 
poorer nutrition intake or status in the NC and 
ONS groups (P < .003). 
Persson 
et al., 
2002 [32] 
137 Colorectal and 
stomach cancer 
(A) Individual support (IS) 
(includes NC and ONS) 
(B) Group rehabilitation (GR) 
(C) IS + GR (ISGR) 
(D) UC 
 
Start: After diagnosis (IS); ~4 
months after diagnosis (GR) 
Duration: 2 years 
2 years Weight gain at 12 and 24 months: Greater in 
those who received IS (IS and ISGR) than those 
who did not (GR and UC) (P < .04); Greater in 
IS + GR group than GR group (P < .02); 
Change in BMI from baseline to 6 months: 
Increased in IS + ISGR group (P = .003); No 
significant difference in GR + UC group. 
QoL and survival: No significant difference 
between groups.   
Isenring 
et al., 
2003 [23] 
36 Head and neck 
cancer; RT 
(A) NC (following ADA-
MNT protocol; ONS provided 
if req) 
(B) UC (general advice from 
nurse + information booklet + 
ONS if req) 
 
Start: After start of RT 
Duration: 3 months 
3 months Weight loss: Smaller in NC group than UC 
group (-1.1 kg vs. -4.3 kg, P = 0.019); FFM 
loss: Smaller in the NC group than the UC 
group (-0.3 kg vs. -2.2 kg, P = 0.029); Fat mass 
loss: No significant difference. 
- 
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Author, 
date 
n Main inclusion 
criteria 
Intervention Length of 
follow-up 
Nutrition status outcomes Other outcomes 
Isenring 
et al., 
2004 [28] 
60 Gastrointestinal tract, 
head and neck cancer; 
RT 
(A) NC (following ADA-
MNT protocol) (ONS 
provided if req)  
(B) UC (general nutrition talk 
and booklet + samples of 
ONS) 
 
Start: ≤4 days after starting 
RT 
Duration: 12 weeks 
12 weeks Weight loss: Smaller in NC group than UC 
group (0.4 kg vs. 4.7 kg, P< .001); Proportion 
of patients who were weight stable: Greater in 
NC group than UC group (24% vs. 11%, P = 
0.016); Change in FFM: No significant 
difference; Change in PG-SGA: Decreased 
(improvement) in NC group but increased in 
UC group (-1.6 vs. 3.1, P = 0.02). 
Global QoL and physical function: Less 
deterioration and more rapid recovery over 
time in NC group than the UC group (P< 
.012).  
Isenring 
et al., 
2007 [27] 
60 Gastrointestinal tract, 
head and neck cancer; 
RT 
(A) NC (following ADA-
MNT protocol) (ONS 
provided if req)  
(B) UC (general nutrition talk 
and booklet + samples of 
ONS) 
 
Start: ≤4 days after starting 
RT 
Duration: 12 weeks 
12 weeks Number of malnourished (assessed using PG-
SGA global score) patients: Lower in NC 
group than UC group at 8 weeks (8 vs. 18, P = 
.020); No significant difference at 12 weeks. 
Energy and protein intake: Higher in NC 
group than UC group (P< .029). 
van den 
Berg et 
al., 2010 
[21] 
38 Head and neck cancer 
(Stage II to IV); RT 
(A) NC + ONS (TF if req) 
(B) UC 
 
Start: After start of RT  
Duration: 16 weeks (till end 
of rehabilitation) 
20 weeks Weight loss at 2 months after RT:  
Smaller in NC group than UC group (P = .03); 
Number of malnourished patients (≥ 5% 
weight loss within 1 month): Decreased over 
time in NC group but increased in UC group (P 
= .02); Lower in NC group than UC group 2 
weeks after RT (0 vs. 5, P = .02); BMI: No 
significant difference. 
- 
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Author, 
date 
n Main inclusion 
criteria 
Intervention Length of 
follow-up 
Nutrition status outcomes Other outcomes 
Corry et 
al., 2008 
[33] 
33 Squamous cell head 
and neck cancer 
(stages III and IV); 
≥10% weight loss 
before RT; Receiving 
RT or CRT 
(A) PEG 
(B) NGT  
 
Start: Not stated 
Duration: Till nutrition 
supplementation was not 
needed 
6 months Weight loss: Greater in NGT group than PEG 
group at 6 weeks post-treatment (3 kg vs. 1.25 
kg, P = .001); No significant difference at 6 
months post-treatment; Lower triceps skinfold 
thickness: Lower in NGT group than PEG 
group at 6 weeks post treatment (9.5 mm vs. 
13.5 mm, P = 0.03). 
Complication rates and patient 
satisfaction: No significant difference; 
Duration of feeding: Longer in PEG group 
than NGT group (139 days vs. 66 days, P = 
.0006). 
Silander 
et al., 
2012 [15] 
134 Advanced head and 
neck cancer; Treated 
with curative intent 
(palliative treatment 
patients excluded) 
(A) PEG (Fibre-containing 
liquid formulation providing 
20 grams of protein and 515 
kcal per 500 mL) 
(B) UC (NC and TF if 
necessary) 
Start: Not stated 
Duration: Not stated 
2 years Weight loss after 6 months: Smaller in PEG 
group than UC group among patients who lost 
weight (11.4% vs. 13.6%, P = .03); Number of 
malnourished patients (>10% unintended 
weight loss during the last 6 months): 
Consistently ~10% less in PEG group than UC 
group; BMI: No significant difference; 
Number of patients with BMI <20: Slightly 
higher in PEG group than control group at 
diagnosis, 6 months and 2 years but lower at 1 
year. 
Length of hospital stay: No significant 
difference; QoL: Several functions better in 
PEG group than UC group at 3, 6 and 12 
months (P < .04). 
Salas et 
al., 2009 
[34] 
39 Squamous cell head 
and neck cancer 
(stages III and IV); 
<10% weight loss 
during last 6 months; 
Receiving CRT 
(A) Systematic PEG (used 
before beginning of CRT) 
(B) UC (PEG used only when 
necessary) 
Start: Before start of CRT 
Duration: ~1.5 months 
6 months Change in BMI: No significant difference. QoL at 6 months: Greater in PEG group than 
UC group (P = .001); Mortality at 6 months: 
No significant difference. 
Abbreviations: ADA-MNT, American Dietetic Association Medical Nutrition Therapy; BMI, body mass index; CRT, chemoradiotherapy; CT, chemotherapy; FF<; fat-free 
mass; GR, group rehabilitation; IS, individual support; ISGR, individual support and group rehabilitation; NC, nutrition counselling; NGT, nasogastric tube feeding; NI, no 
intervention; ONS, oral nutrition supplements; PEG, percutaneous endoscopic gastrostomy feeding; PG-SGA, patient-generated subjective global assessment; PPDI, patient-
participation-based dietary intervention; QoL, quality of life; RCTs, randomised controlled trials; RT, radiotherapy; TF, tube feeding; UC, usual care 
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